Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
April 11, 2023 07:12 AM EDT
Deals

Ex­tend­ed FTC re­view adds wrin­kle to Sanofi's $2.9B Proven­tion Bio buy­out

Amber Tong

Sanofi is ex­tend­ing the dead­line for its $2.9 bil­lion ac­qui­si­tion of Proven­tion Bio to give an­titrust reg­u­la­tors more time to re­view the deal.

The French …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA says Ozem­pic, We­govy short­age is over

Kevin Tang's Con­cen­tra tries to dis­rupt pro­posed Ace­lyrin-Alu­mis merg­er

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Mer­ck KGaA tees up changes to lead­er­ship team; Ex-CVS Health CEO joins Ther­mo Fish­er’s board

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times